Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez M, Honan E, Yang M, Chia P, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi M, Accordino M, Crew K, Hershman D, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer 2022, 4: 257-275. PMID: 36585452, PMCID: PMC9992270, DOI: 10.1038/s43018-022-00489-5.Peer-Reviewed Original ResearchConceptsBreast cancerDose-escalation clinical trialHDAC6 inhibitor ricolinostatMetastatic breast cancerPan-HDAC inhibitorsHistone deacetylaseHuman breast cancerIndividual histone deacetylaseSensitive cancer cellsNab-paclitaxelClinical responseMetastatic BCPredictive biomarkersClinical trialsClinical activityPreclinical studiesTumor typesHDAC6 activityCancer cellsHDAC6iAnticancer strategyPatientsRicolinostatCancerMultiple cohorts